TY - JOUR
T1 - Recent advances in anaplastic thyroid cancer management
AU - Hamidi, Sarah
AU - Maniakas, Anastasios
N1 - Publisher Copyright:
© 2023 Wolters Kluwer Health, Inc.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Purpose of review To summarize recent developments in the diagnosis and management of patients with anaplastic thyroid cancer (ATC). Recent findings An updated edition of the Classification of Endocrine and Neuroendocrine Tumors was released by the World Health Organization (WHO), in which squamous cell carcinoma of the thyroid are now a subtype of ATC. Broader access to next generation sequencing has allowed better understanding of the molecular mechanisms driving ATC and improved prognostication. BRAF-targeted therapies revolutionized the treatment of advanced/metastatic BRAFV600E-mutated ATC, offering significant clinical benefit and allowing better locoregional control of disease through the neoadjuvant approach. However, inevitable development of resistance mechanisms represents a major challenge. Addition of immunotherapy to BRAF/MEK inhibition has shown very promising results and significant improvement in survival outcomes. Summary Major advancements took place in the characterization and management of ATC in recent years, especially in patients with a BRAF V600E mutation. Still, no curative treatment is available, and options are limited once resistance to currently available BRAF-targeted therapies develops. Additionally, there is still a need for more effective treatments for patients without a BRAF mutation.
AB - Purpose of review To summarize recent developments in the diagnosis and management of patients with anaplastic thyroid cancer (ATC). Recent findings An updated edition of the Classification of Endocrine and Neuroendocrine Tumors was released by the World Health Organization (WHO), in which squamous cell carcinoma of the thyroid are now a subtype of ATC. Broader access to next generation sequencing has allowed better understanding of the molecular mechanisms driving ATC and improved prognostication. BRAF-targeted therapies revolutionized the treatment of advanced/metastatic BRAFV600E-mutated ATC, offering significant clinical benefit and allowing better locoregional control of disease through the neoadjuvant approach. However, inevitable development of resistance mechanisms represents a major challenge. Addition of immunotherapy to BRAF/MEK inhibition has shown very promising results and significant improvement in survival outcomes. Summary Major advancements took place in the characterization and management of ATC in recent years, especially in patients with a BRAF V600E mutation. Still, no curative treatment is available, and options are limited once resistance to currently available BRAF-targeted therapies develops. Additionally, there is still a need for more effective treatments for patients without a BRAF mutation.
UR - http://www.scopus.com/inward/record.url?scp=85170294554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85170294554&partnerID=8YFLogxK
U2 - 10.1097/MED.0000000000000823
DO - 10.1097/MED.0000000000000823
M3 - Review article
C2 - 37410453
AN - SCOPUS:85170294554
SN - 1752-296X
VL - 30
SP - 259
EP - 264
JO - Current Opinion in Endocrinology, Diabetes and Obesity
JF - Current Opinion in Endocrinology, Diabetes and Obesity
IS - 5
ER -